.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Pfizer has teamed up with Summit Therapeutics to assess whether one of the indus...
As OS Therapies prepares to take its bacteria-based cancer asset to the FDA for ...
New Approach Methodologies EU-IN Horizon Scanning Report
The Trump administration has started quietly rehiring some of the FDA employees ...
Annex to 24-27 February 2025 CHMP Agenda
Agenda of the CHMP meeting 24-27 February 2025
Hear from UCB’s Brad Chapman on the importance of inclusion, representation, and...
Sanofi has shared a deeper dive into its 469 million euro bowel disease bet, pub...
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluti...
Human medicines European public assessment report (EPAR): Relvar Ellipta, flutic...
Fortrea's CTO discusses AI's expanding role in clinical trials, from discovery t...
Avoid common pitfalls in EU orphan drug market access—learn how local expertise ...
Review of transparency rules for the EU Clinical Trials Information System (CTIS)
Venture capital firm Kineticos Life Sciences has launched a new biotech to take ...
Generic drugmaker Stada is preparing for what could be Europe’s biggest IPO this...
European Medicines Agency procedural advice for users of the centralised procedu...
European Medicines Agency procedural advice for users of the centralised procedu...
European Medicines Agency pre-authorisation procedural advice for users of the c...
European Medicines Agency pre-authorisation procedural advice for users of the c...
Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, ...
Marketing authorisation application (MAA) - pre-submission interactions form